[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-423817-105":59,"doc-detail-423817-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","randomized-trial-of-probiotics-and-nicotinic-acid-on-gut-microbiome-quality-of-life-in-parkinsons","Randomized Trial of Probiotics and Nicotinic Acid on Gut Microbiome, Quality of Life in Parkinson’s","","Evidence suggests probiotics and nicotinic acid (vitamin B3) may improve Parkinson’s disease symptoms and outcomes through gut microbiome modulation. This 12-week, placebo-controlled randomized clinical trial assessed changes in constipation, drug efficacy indicators, neuroendocrine levels, and quality of life among 48 participants. Interventions included probiotics plus nicotinic acid, probiotics plus placebo, or dual placebo. Outcomes were evaluated at baseline, midpoint, and end using symptom scales and gut microbiome analysis via next-generation sequencing, with improvements favoring the probiotics and nicotinic acid group for constipation, quality of life, and microbiome diversity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/randomized-trial-of-probiotics-and-nicotinic-acid-on-gut-microbiome-quality-of-life-in-parkinsons/423817/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/randomized-trial-of-probiotics-and-nicotinic-acid-on-gut-microbiome-quality-of-life-in-parkinsons/423817.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary purpose of the 12-week randomized trial?","Question",{"text":113,"@type":114},"To determine whether a 12-week placebo-controlled randomized clinical trial would change constipation, drug efficacy indicators, neuroendocrine levels, and quality of life in people diagnosed with Parkinson’s disease.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were participants assigned to treatment groups?",{"text":118,"@type":114},"Forty-eight participants were randomly assigned to three groups: probiotics plus nicotinic acid, probiotics plus placebo, or dual placebo for 12 weeks.",{"name":120,"@type":111,"acceptedAnswer":121},"Which outcomes improved in the probiotics and nicotinic acid group compared with placebo?",{"text":122,"@type":114},"Improvements were reported in constipation-related problems, MDS-UPDRS and PDQ-39-related measures, quality-of-life scores, and communication issues, alongside microbiome diversity and composition differences.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},423817,1790794546,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":81,"preview_page_count":4},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","716 Innovation in Aging, 2025, Vol. 9, No. S2  \nSeveral differences became more pronounced after 12 weeks compared with 6 weeks of intervention. Nicotinic acid appeared to have a stabilizing effect on the gut microbiome. The findings suggest that supplementation for twelve weeks may benefit constipation symptoms, gut microbiome, and quality of life measures.  \nAbstract citation ID: igaf122.2438  \nRANDOMIZED TRIAL OF PROBIOTICS AND  \nNICOTINIC ACID ON GUT MICROBIOME, QUALITY  \nOF LIFE IN PARKINSON’S  \nZaw Wai Htoo1, Lydia Zeglin2, Linda Yarrow2, and  \nMark Haub2, 1. University of California Cooperative Extension, Novato, California, United States, 2. Kansas State University, Manhattan, Kansas, United States  \nEvidence suggests that probiotics and nicotinic acid (vitamin B3) may improve symptoms and outcomes of Parkinson’s disease through gut microbiome modulation. This study aimed to determine whether a 12-week placebo-controlled randomized clinical trial would result in changes in constipation, drug efficacy, neuroendocrine levels, and quality of life in people diagnosed with Parkinson’s disease. Forty-eight participants were randomly assigned to one of three groups: (1) probiotics + nicotinic acid,(2) probiotics + placebo, or (3) dual placebo for 12 weeks.  \nConstipation, depression, anxiety, quality of life, mood, symptoms, and nutrition were assessed at baseline, midpoint, and the end of the trial. Blood and stool samples were collected for blood chemistry and gut microbiome analysis using next-generation sequencing (16S rRNA genes, Illumina MiSeq). Statistical significance was set at p \u003C 0.05. The results showed improvements in constipation problems, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Parkinson’s Disease Questionnaire-39 (PDQ-39), quality-of-life scores, and communication issues in probiotics and nicotinic acid groups compared with the placebo group. Blood chemistry remained within normal reference ranges. Supplementation did not change assessments of anxiety, depression, or mood. Gut microbiome analyses showed significant differences in alpha and beta diversity, as well as distinct microbiome compositions related to different interventions, disease status, anxiety, and depression.","cbCaisT4DRhOp3Xz","https://ap.wps.com/l/cbCaisT4DRhOp3Xz","pdf",651465,"English","# Study Aim and Design\n## Participants and Interventions\n## Assessments and Microbiome Methods\n## Results and Outcomes","[{\"question\":\"What was the primary purpose of the 12-week randomized trial?\",\"answer\":\"To determine whether a 12-week placebo-controlled randomized clinical trial would change constipation, drug efficacy indicators, neuroendocrine levels, and quality of life in people diagnosed with Parkinson’s disease.\"},{\"question\":\"How were participants assigned to treatment groups?\",\"answer\":\"Forty-eight participants were randomly assigned to three groups: probiotics plus nicotinic acid, probiotics plus placebo, or dual placebo for 12 weeks.\"},{\"question\":\"Which outcomes improved in the probiotics and nicotinic acid group compared with placebo?\",\"answer\":\"Improvements were reported in constipation-related problems, MDS-UPDRS and PDQ-39-related measures, quality-of-life scores, and communication issues, alongside microbiome diversity and composition differences.\"}]","Randomized Trial of Probiotics and Nicotinic Acid on Gut Microbiome, Quality of Life in Parkinson’s | PDF",1790632032]